Congress
$1,001–$15,000
Traded Dec 3, 2025 · disclosed 2 days later
3 different filers disclosed AMGN within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 20, 2025 · Filed Nov 22, 2025
Amgen's SVP & CCO sold $506K of Amgen shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$505,894
Shares × reported transaction price
16 days after results of Nov 4, 2025, 75 days before results of Feb 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $336.07 on Nov 20, 2025, within 3% of its 52-week high, after a 14% rise over the previous 30 trading days
52-week range $258.59 (Jan 6, 2025) to $343.99 (Nov 18, 2025), 91% of the way up, from 250 adjusted closes. 30 trading days earlier: $295.43 on Oct 9, 2025. Describes the past only, not a forecast
RSI 68, 14% above its 200-day average, 12% above its 50-day average, 2% below the 52-week high, 20-day volatility 34% a year, against the S&P 500: +16 points over 1 month, +13 points over 3 months, +12 points over 6 months
From the adjusted closes up to Nov 20, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Imdelltra on Nov 19, 2025, 1 day before this trade.
New use approved (efficacy supplement). Active ingredient: Tarlatamab-Dlle. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.9% | +1.7% | −0.8% |
| 30 days | −0.1% | +3.2% | −3.3% |
| 90 days | +13.5% | +2.0% | +11.5% |
| 180 days | +0.5% | +12.2% | −11.8% |
Past results only. Not a forecast.
Congress
Traded Dec 3, 2025 · disclosed 2 days later
3 different filers disclosed AMGN within 90 days.
Congress
Traded Dec 3, 2025 · disclosed 2 days later
3 different filers disclosed AMGN within 90 days.
Insider filing
Traded Nov 20, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.